Literature DB >> 7296753

Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits.

I A Taha, R A Ahmad, H J Rogers.   

Abstract

A simple and specific quantitative high-performance thin-layer chromatographic (HPTLC) assay for melphalan in plasma is described. This assay was linear over the investigated range of 50--3,000 ng/ml, with a minimum level of detection of 20 ng/ml. Comparison with a high-pressure liquid chromatographic (HPLC) technique yielded similar estimates for melphalan concentrations in human plasma samples. The HPTLC method, unlike the HPLC technique, does not resolve monohydroxymelphalan satisfactorily. The HPTLC method was used to determine the activation energy for in vitro melphalan hydrolysis: this was 14.5 kcal/mole. The pharmacokinetics of melphalan in rabbits were also investigated. The mean t1/2 in four animals was 32.6 +/- 10.3 (S.D.) min and following IV administration to two animals the apparent volumes of distribution were 2.20 and 1.73 l/kg.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296753     DOI: 10.1007/bf00258477

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products.

Authors:  K P Flora; S L Smith; J C Cradock
Journal:  J Chromatogr       Date:  1979-09-14

2.  Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.

Authors:  M H Tattersall; M Jarman; E S Newlands; L Holyhead; R A Milstead; A Weinberg
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

3.  Pharmacology of intravenous melphalan in patients with multiple myeloma.

Authors:  L Brox; L Birkett; A Belch
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

4.  A method for the measurement of L-phenylalanine mustard in the mouse and dog by high-pressure liquid chromatography.

Authors:  R L Furner; L B Mellett; R K Brown; G Duncan
Journal:  Drug Metab Dispos       Date:  1976 Nov-Dec       Impact factor: 3.922

5.  High-pressure liquid chromatographic analysis of melphalan in plasma.

Authors:  S Y Chang; D S Alberts; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

6.  Hydrolysis and protein binding of melphalan.

Authors:  S Y Chang; D S Alberts; D Farquhar; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

7.  Kinetics of intravenous melphalan.

Authors:  D S Alberts; S Y Chang; H S Chen; T E Moon; T L Evans; R L Furner; K Himmelstein; J F Gross
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

8.  The distribution of radioactivity in tissues of the rat following the administration of a nitrogen mustard derivative; p-di-(2-chloroethyl) amino-DL-phenyl[beta-14C] alanine.

Authors:  P COHN
Journal:  Br J Cancer       Date:  1957-06       Impact factor: 7.640

  8 in total
  3 in total

1.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.

Authors:  I A Taha; R A Ahmad; H Gray; C I Roberts; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.